What a life eh, betting that companies developing cutting edge cancer treatments that could end misery and pain for 100s and thousands of people will fail. Then revelling in it.
Well you are a respected poster so I'd go with your suggestions PL75. Can't believe how crap big Al is, you need to WhatsApp him and tell him to pull his finger out.
Not a scientist and I know the primary aims of P1a were to prove safety and tolerability and define an MTD so a dose level could be chosen for phase 1b.
But surely dose wise they would know what they would administer for phase 1b as they would already be at the point of a therapeutic dose being delivered.
Why not just call biologically effective dose now?
I also know that the MHRA may well have stipulated the amount of cohorts before they can do that.